Navigation Links
XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
Date:1/28/2009

VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL) today announced that on January 27, 2009 it received a Staff Determination Letter (the "Letter") from The Nasdaq Stock Market ("Nasdaq") notifying the Company that the staff of Nasdaq's Listing Qualifications Department determined, using its discretionary authority under Nasdaq Marketplace Rule 4300, that the Company's American Depository Shares ("ADRs") would be delisted from Nasdaq. The Letter further stated that Nasdaq would suspend trading in the Company's ADRs at the opening of trading on February 5, 2009 and then file a Form 25-NSE with the Securities and Exchange Commission ("SEC") to deregister the Company's ADRs, unless the Company appeals Nasdaq's delisting determination. Nasdaq's determination to delist the ADRs was based on Nasdaq's belief that the Company was a public shell and that the Company does not meet the stockholder's equity requirement or any of its alternatives.

The Letter also indicated that, in accordance with the procedures set out in Marketplace Rule 4800 Series, the Company would have seven (7) calendar days, or until February 3, 2009, to appeal the delisting from Nasdaq to a Listing Qualifications Panel. At this time, the Company does plan to appeal the delisting from Nasdaq. There can be no assurance that the appeal will be successful.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... DUBAI , UAE, November 24, 2014 ... prestigious "Sheikh Hamdan Bin Rashid Al Maktoum Awards for ... in Dubai, United Arab Emirates , ... http://photos.prnewswire.com/prnh/20141124/717861 ) , The Carter Center ... Medical Services is actively involved in numerous programs that ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 VolitionRx ... developing diagnostic tests for cancer and other conditions, today announced ... presented at the Science for Business BioWin Day 2014, being ... . The data come from VolitionRx,s lung cancer pilot study, ... of the Centre Hospitalier Universitaire (CHU) de Liege in ...
(Date:11/24/2014)... FRANCISCO, Calif. , Nov. 24, 2014   Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... Jaffray 26 th Annual Healthcare Conference on Tuesday, December ... York . The live audio webcast and ... http://investor.veracyte.com . Please connect to the website at least ...
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
Breaking Biology Technology:Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... Universal Detection,Technology (OTC Bulletin Board: UNDT), a ... bioterrorism and other,infectious health threats and provider of ... company,s CEO, Jacques Tizabi,is featured in an exclusive ... interview gives viewers an overview of the company, ...
... Aug. 14 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC ... the leading plasma-based pharmaceutical companies in,the People,s Republic ... second quarter ended June 30, 2008., ... 35.1% year-over-year to $11.9 million -- Gross ...
... Mass., Aug. 14 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... for the second quarter of 2008 was $120,184 compared ... Revenue from the sale,of PCT products and services was ... compared to $136,355 for the prior year period. During ...
Cached Biology Technology:[video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.net's 3-Minute Press Show 2China Biologic Products Reports Second Quarter 2008 Results 2China Biologic Products Reports Second Quarter 2008 Results 3China Biologic Products Reports Second Quarter 2008 Results 4China Biologic Products Reports Second Quarter 2008 Results 5China Biologic Products Reports Second Quarter 2008 Results 6China Biologic Products Reports Second Quarter 2008 Results 7China Biologic Products Reports Second Quarter 2008 Results 8China Biologic Products Reports Second Quarter 2008 Results 9China Biologic Products Reports Second Quarter 2008 Results 10China Biologic Products Reports Second Quarter 2008 Results 11China Biologic Products Reports Second Quarter 2008 Results 12China Biologic Products Reports Second Quarter 2008 Results 13China Biologic Products Reports Second Quarter 2008 Results 14China Biologic Products Reports Second Quarter 2008 Results 15Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 2Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 3Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 4Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 5Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 6Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 7Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 8Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 9
(Date:11/7/2014)... Auguste, associate professor, biomedical engineering, in the Grove ... New York, have identified a molecule that could ... most aggressive forms of breast cancer. , Triple ... rate owing to aggressive proliferation and metastasis and ... Auguste,s team, discovered the overexpression of intercellular adhesion ...
(Date:11/6/2014)... TALLAHASSEE, Fla. -- A groundbreaking paper from a team ... better understanding of how plants could adapt to and ... The research, published in the latest issue of the ... how chromatin (the complex of DNA and proteins) is ... material, so that some genes are turned on and ...
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... a drink problem, there is a greater risk that you ... from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. ... 50% more likely to have a drink problem in the ... new light on this link. Carried out by researcher Anna ...
... LAWRENCE University of Kansas scientists have found new evidence ... (LCPUFA) are good for developing brains and hearts. In ... of four formulas from birth to 12 months; three with ... formula with no LCPUFA, and tested at four, six and ...
... our understanding of genetics and biological processes in all animals, ... of animals, scientists are still finding the fruit fly to ... the University of Rochester. The latest revelation has to ... fruit flies. It was widely accepted that all X chromosomes ...
Cached Biology News:New thinking on regulation of sex chromosomes in fruit flies 2
... number is a new product number, ... number. If showing no availability yet, ... number (E6152) or contact customer service ... diam. 11.25 6.40 in. ...
A convenience pack containing one each of the most popular sizes of Cat. No. 4980 flask. Designed for the low volume user, a case contains one each of five sizes: 50mL, 125mL, 250mL, 500mL, and 1L....
...
...
Biology Products: